다우존스 지수

브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.

등록

홈
인베스팅
주식
미국
NASDAQ
Lixte Biotechnology Holdings Inc (LIXTW)
Lixte Biotechnology Holdings Inc (LIXTW) 뉴스

LIXTW

Lixte Biotechnology (LIXTW)

Lixte Biotechnology Holdings Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:LIXTW

1

일자	시간	출처	헤드라인	심볼	기업
2024/06/15	03:47	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc
2024/06/15	00:00	GlobeNewswire Inc.	LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc
2024/06/14	22:30	GlobeNewswire Inc.	LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc
2024/06/14	21:30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc
2024/06/06	21:30	GlobeNewswire Inc.	Scientific Journal Reports Findings that Show LIXTE’s Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc
2024/06/06	04:55	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc
2024/06/03	21:30	GlobeNewswire Inc.	LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc
2024/05/30	06:29	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc
2024/05/21	06:05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc
2024/05/10	01:00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc
2024/05/09	21:30	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc
2024/05/08	22:25	GlobeNewswire Inc.	LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc
2024/04/25	04:25	AllPennyStocks.com	Mixed Shelf Filing Gives Micro Cap Delayed Boost	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc
2024/03/28	04:35	AllPennyStocks.com	Biotech Steals The Show Following Pre-Clinical Data Announcement	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc
2024/03/27	21:30	GlobeNewswire Inc.	NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc
2024/03/21	21:30	GlobeNewswire Inc.	LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc
2024/02/27	22:30	GlobeNewswire Inc.	Professor René Bernards to Present New Pre-Clinical Data on LIXTE’s LB-100 at Joint Conference of European and American Associations for Cancer Research	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc
2024/02/26	22:30	GlobeNewswire Inc.	LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc
2024/01/29	22:30	GlobeNewswire Inc.	First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc
2023/11/13	22:30	GlobeNewswire Inc.	LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc
2023/10/16	21:30	GlobeNewswire Inc.	LIXTE, Netherlands Cancer Institute, and Oncode Institute to Expand Collaboration	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc
2023/10/09	21:30	GlobeNewswire Inc.	LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc
2023/09/26	21:30	GlobeNewswire Inc.	LIXTE Appoints Bas van der Baan as President and Chief Executive Officer	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc
2023/09/20	21:30	GlobeNewswire Inc.	LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc
2023/07/21	05:05	GlobeNewswire Inc.	LIXTE Biotechnology Announces Closing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc
2023/07/18	21:00	GlobeNewswire Inc.	LIXTE Biotechnology Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc
2023/07/17	21:30	GlobeNewswire Inc.	Preclinical Results of LIXTE Biotechnology’s Collaboration with Netherlands Cancer Institute Reveal Novel Mechanism by which LIXTE’s Lead Clinical Compound LB-100 Enhances Effectiveness of Immunotherapy and Chemotherapy	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc
2020/12/02	02:30	GlobeNewswire Inc.	Lixte Biotechnology Holdings, Inc. Announces Closing of Public Offering and Uplisting to Nasdaq	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc
2020/12/01	05:52	Business Wire	WestPark Capital Announces Closing of $5,700,000 Follow-On Offering & NASDAQ Up-listing of Lixte Biotechnology Holdings, Inc....	NASDAQ:LIXTW	Lixte Biotechnology Holdings Inc

검색 관련기사 보기:NASDAQ:LIXTW

1

Health Care Select Sector

Financial Select Sector

US Dollar vs Euro

Deutsche Telekom (QX)

Energy Select Sector SPDR

US Dollar vs Yen

Bank of America

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관